CDK4 and breast carcinoma: Although the rates of RB mutation are higher in TNBC (7%; ref. 20), the RB dependence of CDK4/6 inhibitor–mediated radiosensitization may be an important consideration in patient selection for future clinical trials in both ER+ breast cancer and TNBC.